Camlipixant

DRUG5 trials

Sponsors

Bellus Health Inc. - a GSK company, GlaxoSmithKline

Conditions

CoughHealthyIrritable Bowel Syndrome

Phase 1

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

CompletedNCT05899829

Bellus Health Inc. - a GSK companyCough, Healthy

Start: 2023-06-21End: 2023-08-08Updated: 2024-12-04

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

CompletedNCT05959447

Bellus Health Inc. - a GSK companyCough, Healthy

Start: 2023-07-26End: 2023-10-13Updated: 2025-03-26

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

CompletedNCT06222892

Bellus Health Inc. - a GSK companyCough

Start: 2024-02-02End: 2024-12-30Updated: 2026-01-07

A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes

WithdrawnNCT07684586

GlaxoSmithKlineCough

Start: 2026-07-02End: 2027-08-27Updated: 2026-08-31

Phase 2

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

RecruitingNCT07519395

GlaxoSmithKlineIrritable Bowel Syndrome

Start: 2026-04-08End: 2027-07-13Target: 420Updated: 2026-06-25